Matthew Wagener is the Vice President of CRO Services at Proxima Clinical Research, a contract research organization that serves the emerging drug and medical device industries.
Matt has over 15 years of industry experience working across multiple life science businesses in key areas including clinical operations, business operations, and business development.
Prior to joining the Proxima team, he was a member of the executive team and the Sr. Director of Corporate Operations at MedSource, a CRO focused on Oncology, Neurology, and Rare Diseases. While at MedSource, Matt successfully managed corporate operations and business development through high growth period (57% CAGR over five years) building operations to support growth. Prior to MedSource he held several management positions at McKesson Specialty Health / US Oncology. At US Oncology Matt led clinical and business operations for the launch of their oncology CRO through start-up, full service clinical trial operations, and business acquisition. Prior to managing the CRO business unit at US Oncology, he led clinical development for the Lung, GI, Hematology, and Radiation Oncology research programs.
He also held other research positions at the University of Texas Medical Branch in Galveston in the department of Orthopedic Surgery and MD Anderson Cancer Center in the department of Radiation Oncology. He received his degree in biomedical science from Texas A&M University. Since starting his career in research, he has worked in key sections of basic and clinical research from bench to bedside to management.
Texas A&M University: Biomedical Science, B.S.
Proxima Clinical Research, Inc., Houston, Texas
Vice President CRO Services
Vice President Clinical Operations
MedSource, Houston, Texas (acquired by Ergomed PLC)
Senior Director Corporate Operations
McKesson, Inc., Woodlands, Texas
Director, Research Business Development and Alliances
US Oncology Clinical Development, LLC, Woodlands, Texas (acquired by McKesson)
Associate Director, CRO Clinical and Business Operations
Manager, Clinical and Business Development
US Oncology Research, Inc., Woodlands, Texas (acquired by McKesson)
Manager, Clinical Development
University of Texas Medical Branch, Galveston, Texas
Research Coordinator
MD Anderson Cancer Center, Houston, Texas
Research Assistant
Mr. Wagener has played an important role in the development of the following medical products:
- In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
- Medical device for treatment of intracranial bifurcation aneurysms
- Medical device for liver transplant
- Medical device for prostate cancer ablation
- In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
- Medical device (noninvasive transcutaneous spinal cord stimulation) to enhance upper extremity function
- Medical device for imaging and analysis of tissue during breast cancer surgery
- First in human dose finding study of investigational drug product
- Pre-IND and IND filing for biologic product for solid tumors and lung cancer
- Pre-IND filing for drug product for COVID-19 treatment
- Drug product for tardive dyskinesia
- CAR-T therapy for oncology
- Stem cell therapy for oncology
- Bleed detection and monitoring device during endovascular procedures
- Numerous studies for lung cancer, gastrointestinal cancers, and hematologic malignancies
- Medical devices for total hip replacement/arthroplasty
- Medical device for pain management following total knee replacement/arthroplasty
- Medical device for diabetic foot ulcers
- Medical device for wound care
